Orthocell Ltd (AU:OCC)
ASX:OCC
Want to see AU:OCC full AI Analyst Report?
OCC Stock Chart & Stats
AU$0.81
AU$0.07(4.58%)
At close: 4:00 PM EST
AU$0.81
AU$0.07(4.58%)
Day’s Range― - ―
52-Week RangeAU$0.70 - AU$1.60
Previous CloseN/A
Volume2.26M
Average Volume (3M)820.75K
Market Cap
AU$206.91M
Enterprise ValueAU$163.36M
Total Cash (Recent Filing)AU$44.37M
Total Debt (Recent Filing)AU$835.79K
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 28, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding272,253,630
10 Day Avg. Volume747,972
30 Day Avg. Volume820,745
Financial Highlights & Ratios
PEG Ratio-3.76
Price to Book (P/B)18.08
Price to Sales (P/S)34.89
P/FCF Ratio-29.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.21Price Target Upside48.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$12.23M
Bulls Say, Bears Say
Bulls Say
Focused Commercial Product (Remplir)Having a defined, commercial-stage product (Remplir) gives Orthocell a clear revenue engine and product-market fit in peripheral nerve repair. A single, specialty surgical product supports predictable hospital procurement cycles and focused go-to-market efforts, aiding scalable commercialization over months.
Top-line Growth TrendConsistent revenue growth indicates expanding clinical adoption and improving market penetration for Orthocell’s products. Sustainable top-line momentum provides runway to invest in commercial infrastructure and R&D, supporting longer-term margin improvement if growth continues and fixed costs are leveraged.
Low Financial LeverageA very low debt-to-equity ratio reflects conservative leverage and a healthy capital structure, giving the company financial flexibility. This reduces bankruptcy risk and preserves capacity to raise incremental funding or redirect cash to commercialization and trials without heavy interest burdens.
Bears Say
Persistent UnprofitabilityOngoing negative margins and losses undermine the company’s ability to self-fund growth and reduce resilience to adverse events. Persistent unprofitability pressures returns on invested capital and will likely require repeated external financing, diluting shareholders and constraining long-term margin sustainability.
Negative Operating Cash FlowDespite some free cash flow growth, continued negative operating cash flow indicates an operational cash burn. This structural cash shortfall forces reliance on financing to fund commercialization and trials, limiting investment optionality and increasing execution risk over the next several quarters.
Regulatory And Adoption DependencyRevenue and commercial expansion are dependent on regulatory approvals, reimbursement decisions and surgeon adoption. These structural external dependencies can materially delay or restrict market access, slowing sustainable revenue growth and creating multi-quarter execution risk for commercialization plans.
Orthocell Ltd News
OCC FAQ
What was Orthocell Ltd’s price range in the past 12 months?
Orthocell Ltd lowest share price was AU$0.70 and its highest was AU$1.60 in the past 12 months.
What is Orthocell Ltd’s market cap?
Orthocell Ltd’s market cap is AU$206.91M.
When is Orthocell Ltd’s upcoming earnings report date?
Orthocell Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 79 days.
How were Orthocell Ltd’s earnings last quarter?
Orthocell Ltd released its earnings results on Feb 23, 2026. The company reported -AU$0.021 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.021.
Is Orthocell Ltd overvalued?
According to Wall Street analysts Orthocell Ltd’s price is currently Undervalued.
Does Orthocell Ltd pay dividends?
Orthocell Ltd does not currently pay dividends.
What is Orthocell Ltd’s EPS estimate?
Orthocell Ltd’s EPS estimate is 0.
How many shares outstanding does Orthocell Ltd have?
Orthocell Ltd has 272,253,630 shares outstanding.
What happened to Orthocell Ltd’s price movement after its last earnings report?
Orthocell Ltd reported an EPS of -AU$0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Orthocell Ltd?
Currently, no hedge funds are holding shares in AU:OCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orthocell Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.21 (48.77% Upside)
AU$1.21 (48.77% Upside)
Blogger Sentiment
Bullish
AU:OCC Sentiment 96%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$44.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.48%
12-Months-Change
Fundamentals
Return on Equity
-44.80%
Trailing 12-Months
Asset Growth
49.36%
Trailing 12-Months
Company Description
Orthocell Ltd
Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries. The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries. Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle. Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.
OCC Stock 12 Month Forecast
Average Price Target
AU$1.21
▲(48.77% Upside)
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Mesoblast Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Options Prices
Currently, No data available
---